Diabetes

Intensive Glycemic Control May Cut CV Autonomic Neuropathy Risk

Publish Date January 15, 2021

Greatest CAN prevention effect seen among type 2 diabetes patients without cardiovascular disease history.

Euglycemic DKA ID’d in T2DM Patients With COVID-19

Publish Date January 12, 2021

Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS-CoV-2 infection.

Age at T2DM Diagnosis Inversely Linked to Risk for Adverse Outcomes

Publish Date January 5, 2021

One-year increase in age at diabetes diagnosis linked to lower risk for all-cause mortality and macrovascular, microvascular disease.

Risk of Severe COVID-19 Up Among Those With Diabetes

Publish Date December 31, 2020

Risk for severe COVID-19 similar among those with type 1 and type 2 diabetes

Metformin Use May Reduce Mortality in Women With COVID-19

Publish Date December 17, 2020

In overall sample of men and women, metformin use was not linked to significantly reduced mortality

No Significant Difference Between Sitagliptin, Placebo in Pediatric T2D Trials

Publish Date December 15, 2020

The alert was based on data from three 20-week double-blind, placebo-controlled studies each with 34-week extensions.

Canagliflozin Beneficial Even for Advanced Kidney Disease

Publish Date December 9, 2020

Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m² with no increase in AKI

Risk for Fatal Cardiovascular Events High in Many T2DM Patients

Publish Date December 7, 2020

More than one-third of T2DM patients without established cardiovascular disease had very high risk for CV events

Comparative Performance of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes

Publish Date November 8, 2020

Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.

Diabetes Increases Risk of In-Hospital Mortality in Patients With COVID-19

Publish Date October 19, 2020

Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.